Vascular Biosciences
Pre-clinicalCARSKNKDC (CAR) peptide, our lead therapeutic candidate, is being developed for the enhanced survival and treatment of pulmonary hypertension, COVID-19 and sepsis patients. CAR preferentially homes to, and penetrates diseased tissue while selectively augmenting the efficacy of therapies. CAR can selectively boost drug effectiveness and reduce systemic side effects by enhancing the targeted uptake of co-administered and conjugated therapeutics.
About
CARSKNKDC (CAR) peptide, our lead therapeutic candidate, is being developed for the enhanced survival and treatment of pulmonary hypertension, COVID-19 and sepsis patients. CAR preferentially homes to, and penetrates diseased tissue while selectively augmenting the efficacy of therapies. CAR can selectively boost drug effectiveness and reduce systemic side effects by enhancing the targeted uptake of co-administered and conjugated therapeutics.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile